Exelixis Inc Number of Reportable Segments
Exelixis Inc (EXEL) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-05
- Exelixis Inc number of reportable segments for the quarter ending 2026-04-03 was 1.00 segment.
- Exelixis Inc number of reportable segments for the quarter ending 2017-03-31 was 1.00 segment.
- Exelixis Inc number of reportable segments for fiscal 2026 was 1.00 segment.
- Exelixis Inc number of reportable segments for fiscal 2018 was 1.00 segment, a 0.00% change from fiscal 2017.
- Exelixis Inc number of reportable segments for fiscal 2017 was 1.00 segment, a 99.90% decline from fiscal 2016.
- Exelixis Inc number of reportable segments for fiscal 2016 was 1.00K segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-07-03 | 1.00 segment 10-Q · filed 2026-08-05 | |||
| 2026-04-03 | 1.00 segment 10-Q · filed 2026-05-05 | |||
| 2026-01-02 | 1.00 segment 10-K · filed 2026-02-10 | |||
| 2018-12-28 | 1.00 segment 10-K · filed 2019-02-22 | |||
| 2017-12-29 | 1.00 segment 10-K · filed 2018-02-26 | |||
| 2017-09-30 | 1.00 segment 10-Q · filed 2017-11-01 | |||
| 2017-06-30 | 1.00 segment 10-Q · filed 2017-08-02 | |||
| 2017-03-31 | 1.00 segment 10-Q · filed 2017-05-01 | |||
| 2016-12-31 | 1.00K segment 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |